Correlation Analysis Of The Therapeutic Effect Of Recombinant Human Granulocyte Stimulating Factor With PEG In Patients With Ovarian Cancer

Objective: To study the difference between primary prevention and secondary prevention in the application of pegylated recombinant human granulocyte colonystimulating factor(PEG-rhG-CSF)in postoperative chemotherapy for patients with ovarian cancer,and comparative study The application of recombinant human granulocyte stimulating factor(rhG-CSF)drug therapy and clinical data analysis of non-drugs provides a clinical basis for the more reasonable application of PEG-rhG-CSF in patients with ovarian cancer after chemotherapy.Methods: A total of 50 patients with postoperative chemotherapy for ovarian cancer were enrolled from the First Affiliated Hospital of Xinjiang Medical University from October 2017 to December 2018.Three patients were lost to follow-up.PEG-rhG-CSF was finally included according to the application of whitening drugs after chemotherapy.10 patients in the primary prevention group,14 in the secondary prevention group,13 patients in the rhG-CSF treatment group and 10 patients in the leukocyte-free drug group after chemotherapy,and the relevant clinical data in each group of chemotherapy for 3 cycles were extracted for comparative analysis.Methods Statistical SPSS 25.0 software was used.The data were analyzed by T test or rank sum test.The changes of white blood cells in each group were taken.The average value of white blood cell counts was calculated on the same day,and GraphPad 8.0.1 was used for mapping analysis.Results: By comparing the number of fevers,the number of infections,the number of hospitalization delays,and the number of dose restrictions,the primary prevention group had a significant advantage over the other groups.The situation in the primary prevention group was significantly reduced or not.The other groups were compared by t test.The results showed that the PEG-rhG-CSF secondary prevention group was significantly different from the untreated group(t=-0.600,p=0.036 P value<0.05),that is,the secondary prevention group was more clinically compared with the untreated group.The effect also has obvious advantages.The PEG-rhG-CSF secondary preventiongroup and the rhG-CSF treatment group(t=-1.777,p=0.024 P value<0.05)were significantly different,and the untreated group and the treated group(t=-2.141,p=0.022 P value<0.05)The difference was significant.The patients in the rhG-CSF-treated group decreased to the treatment standard because of the decrease of the patient's cell level,so the comparison with the rhG-CSF treatment group was low,and no comparison was made.The primary prevention group maintains leukocytes at a certain level throughout the chemotherapy cycle.Conclusion: Primary prevention of PEG-rhG-CSF after chemotherapy with TC regimen in patients with ovarian cancer is more advantageous than PEG-rhG-CSF secondary prevention in terms of safety and efficacy.Safety-related primary prevention of PEG-rhG-CSF It is a better choice.